Browse ACACA

Summary
SymbolACACA
Nameacetyl-CoA carboxylase alpha
Aliases acetyl-CoA carboxylase 1; ACAC; ACC; acetyl-Coenzyme A carboxylase alpha; ACACD; ACC-alpha
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm.
Domain PF08326 Acetyl-CoA carboxylase
PF02785 Biotin carboxylase C-terminal domain
PF00289 Biotin carboxylase
PF00364 Biotin-requiring enzyme
PF01039 Carboxyl transferase domain
PF02786 Carbamoyl-phosphate synthase L chain
Function

Catalyzes the rate-limiting reaction in the biogenesis of long-chain fatty acids. Carries out three functions: biotin carboxyl carrier protein, biotin carboxylase and carboxyltransferase.

> Gene Ontology
 
Biological Process GO:0001894 tissue homeostasis
GO:0006084 acetyl-CoA metabolic process
GO:0006631 fatty acid metabolic process
GO:0006633 fatty acid biosynthetic process
GO:0006637 acyl-CoA metabolic process
GO:0006732 coenzyme metabolic process
GO:0006766 vitamin metabolic process
GO:0006767 water-soluble vitamin metabolic process
GO:0006768 biotin metabolic process
GO:0006790 sulfur compound metabolic process
GO:0006820 anion transport
GO:0006839 mitochondrial transport
GO:0006853 carnitine shuttle
GO:0006869 lipid transport
GO:0009108 coenzyme biosynthetic process
GO:0010876 lipid localization
GO:0015711 organic anion transport
GO:0015718 monocarboxylic acid transport
GO:0015908 fatty acid transport
GO:0015909 long-chain fatty acid transport
GO:0016053 organic acid biosynthetic process
GO:0032365 intracellular lipid transport
GO:0034694 response to prostaglandin
GO:0034695 response to prostaglandin E
GO:0035336 long-chain fatty-acyl-CoA metabolic process
GO:0035337 fatty-acyl-CoA metabolic process
GO:0035338 long-chain fatty-acyl-CoA biosynthetic process
GO:0035383 thioester metabolic process
GO:0035384 thioester biosynthetic process
GO:0044236 multicellular organism metabolic process
GO:0044259 multicellular organismal macromolecule metabolic process
GO:0044268 multicellular organismal protein metabolic process
GO:0044272 sulfur compound biosynthetic process
GO:0044283 small molecule biosynthetic process
GO:0046394 carboxylic acid biosynthetic process
GO:0046942 carboxylic acid transport
GO:0046949 fatty-acyl-CoA biosynthetic process
GO:0048871 multicellular organismal homeostasis
GO:0051186 cofactor metabolic process
GO:0051188 cofactor biosynthetic process
GO:0051259 protein oligomerization
GO:0051260 protein homooligomerization
GO:0051262 protein tetramerization
GO:0051289 protein homotetramerization
GO:0055088 lipid homeostasis
GO:0060249 anatomical structure homeostasis
GO:0071379 cellular response to prostaglandin stimulus
GO:0071380 cellular response to prostaglandin E stimulus
GO:0071616 acyl-CoA biosynthetic process
GO:0072330 monocarboxylic acid biosynthetic process
GO:0098656 anion transmembrane transport
GO:1901654 response to ketone
GO:1901655 cellular response to ketone
GO:1990542 mitochondrial transmembrane transport
GO:2001293 malonyl-CoA metabolic process
GO:2001295 malonyl-CoA biosynthetic process
Molecular Function GO:0003989 acetyl-CoA carboxylase activity
GO:0004075 biotin carboxylase activity
GO:0016421 CoA carboxylase activity
GO:0016874 ligase activity
GO:0016879 ligase activity, forming carbon-nitrogen bonds
GO:0016885 ligase activity, forming carbon-carbon bonds
Cellular Component GO:0015629 actin cytoskeleton
> KEGG and Reactome Pathway
 
KEGG hsa04152 AMPK signaling pathway
hsa04910 Insulin signaling pathway
hsa04922 Glucagon signaling pathway
hsa00061 Fatty acid biosynthesis
hsa00620 Pyruvate metabolism
hsa00640 Propanoate metabolism
hsa01100 Metabolic pathways
hsa01212 Fatty acid metabolism
Reactome R-HSA-2426168: Activation of gene expression by SREBF (SREBP)
R-HSA-196780: Biotin transport and metabolism
R-HSA-163765: ChREBP activates metabolic gene expression
R-HSA-3371599: Defective HLCS causes multiple carboxylase deficiency
R-HSA-3323169: Defects in biotin (Btn) metabolism
R-HSA-3296482: Defects in vitamin and cofactor metabolism
R-HSA-1643685: Disease
R-HSA-5668914: Diseases of metabolism
R-HSA-75105: Fatty Acyl-CoA Biosynthesis
R-HSA-535734: Fatty acid, triacylglycerol, and ketone body metabolism
R-HSA-163685: Integration of energy metabolism
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-196854: Metabolism of vitamins and cofactors
R-HSA-196849: Metabolism of water-soluble vitamins and cofactors
R-HSA-1655829: Regulation of cholesterol biosynthesis by SREBP (SREBF)
R-HSA-75109: Triglyceride Biosynthesis
Summary
SymbolACACA
Nameacetyl-CoA carboxylase alpha
Aliases acetyl-CoA carboxylase 1; ACAC; ACC; acetyl-Coenzyme A carboxylase alpha; ACACD; ACC-alpha
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ACACA and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolACACA
Nameacetyl-CoA carboxylase alpha
Aliases acetyl-CoA carboxylase 1; ACAC; ACC; acetyl-Coenzyme A carboxylase alpha; ACACD; ACC-alpha
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ACACA in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolACACA
Nameacetyl-CoA carboxylase alpha
Aliases acetyl-CoA carboxylase 1; ACAC; ACC; acetyl-Coenzyme A carboxylase alpha; ACACD; ACC-alpha
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ACACA in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0180.946
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0710.953
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.090.928
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2610.352
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4890.845
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0260.994
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1330.728
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0220.989
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2460.893
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 4801
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 2801
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0630.433
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ACACA in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.45.51.90.66
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.45.12.30.647
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)2117195.913.10.355
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.516.7-4.21
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131123.1023.10.223
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382715.8015.80.037
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221322.7022.70.134
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolACACA
Nameacetyl-CoA carboxylase alpha
Aliases acetyl-CoA carboxylase 1; ACAC; ACC; acetyl-Coenzyme A carboxylase alpha; ACACD; ACC-alpha
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ACACA. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolACACA
Nameacetyl-CoA carboxylase alpha
Aliases acetyl-CoA carboxylase 1; ACAC; ACC; acetyl-Coenzyme A carboxylase alpha; ACACD; ACC-alpha
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ACACA. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ACACA.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolACACA
Nameacetyl-CoA carboxylase alpha
Aliases acetyl-CoA carboxylase 1; ACAC; ACC; acetyl-Coenzyme A carboxylase alpha; ACACD; ACC-alpha
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ACACA. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolACACA
Nameacetyl-CoA carboxylase alpha
Aliases acetyl-CoA carboxylase 1; ACAC; ACC; acetyl-Coenzyme A carboxylase alpha; ACACD; ACC-alpha
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ACACA expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolACACA
Nameacetyl-CoA carboxylase alpha
Aliases acetyl-CoA carboxylase 1; ACAC; ACC; acetyl-Coenzyme A carboxylase alpha; ACACD; ACC-alpha
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ACACA and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolACACA
Nameacetyl-CoA carboxylase alpha
Aliases acetyl-CoA carboxylase 1; ACAC; ACC; acetyl-Coenzyme A carboxylase alpha; ACACD; ACC-alpha
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ACACA collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting ACACA.
ID Name Drug Type Targets #Targets
DB00121BiotinSmall MoleculeACACA, ACACB, HLCS, MCCC1, MCCC2, PC, PCCA, PCCB, SLC5A69